Current therapies for Burkitt's lymphoma (BL) utilise combined cytotoxic chemotherapy, but these treatments are not always available in areas where the disease is endemic and are also markedly less successful in AIDS-related BL. Therefore, additional therapies are urgently required. We demonstrate here that combined fibrates and MPA exert powerful, antiproliferative actions against well-characterised Daudi, Raji and L3055 BL cell lines and primary BL cells. Detailed studies in L3055 demonstrated that this activity was mediated by induced apoptosis and confirmed by observations that overexpression of the antiapoptotic genes bcl-2 or bcl-x L conferred significant protection against the drugs. Importantly, since fibrates and MPA are inexpensive and stable with minimal-associated toxicities, we suggest that these drugs should be considered as adjuncts to currently available treatments for BL in endemic and AIDS-related disease.
Introduction
A striking feature of Burkitt's lymphoma (BL) is the aggressive nature of the tumours, which have been reported to double in size in as little as 24 h. [1] [2] [3] The rapid growth of these tumours necessitates prompt diagnosis and prognosis is significantly worse in advanced disease. Current treatment of BL involves combination chemotherapy and achieves high response rates, presumably because the cells' rapid proliferation renders them acutely chemosensitive. 4 However, response rates are considerably poorer in AIDS-related BL owing to the reduced capacity of these patients to tolerate intensive chemotherapy. [5] [6] [7] In addition, intensive chemotherapy and the clinical support that it requires may not be available for many individuals in underdeveloped countries where BL is endemic. Even in developed countries, less intensive therapies associated with reduced systemic toxicities remain desirable. Thus, the development of inexpensive therapies based around drugs with low associated toxicities would represent a major advance in the global management of BL.
Retinoic acids are active metabolites of vitamin A that regulate the differentiation and proliferation of diverse cells. 8 A number of studies have addressed the potential antiproliferative actions of retinoic acids against BL cells and cell lines and have demonstrated that most are relatively insensitive. [9] [10] [11] [12] A recent study by Cariati et al 12 has demonstrated that whereas retinoic acids powerfully inhibited the proliferation of EpsteinBarr virus (EBV) immortalised B-lymphoblastoid cell lines carrying an activated c-myc, they failed to do so in 7/8 BL cell lines despite comparable expression of the retinoic acid receptors. These observations suggest that the malignant status of BL cells is associated with a developed insensitivity to retinoids.
In separate studies, we have shown that the sensitivity of acute myeloid leukemia cells to all-trans retinoic acid (ATRA) can be enhanced several fold by cotreatment with either clofibric acid (CA) or medroxyprogesterone acetate (MPA). 13, 14 We therefore wished to investigate whether these drugs might potentiate the antiproliferative response of BL cell lines to ATRA. Surprisingly, whereas ATRA had no antiproliferative activity against Daudi, Raji or L3055 cells both CA and MPA were active and markedly so when used in combination (CA/MPA). Importantly, CA/MPA also exhibited antiproliferative activity against primary BL cells. The doses of these drugs used in our studies equate to those already in clinical use for the treatment of other diseases. Thus, the reported actions of the drugs against BL cells suggest that they could serve as powerful adjuncts to current therapies.
Materials and methods

Cells and cell lines
The Raji and Daudi BL cell lines were maintained in RPMI 1640 medium (Gibco, Invitrogen Corporation, Invitrogen Ltd, Paisley, UK) containing penicillin (100 U/ml), streptomycin (100 mg/ml) (Gibco) and 10% v/v heat-inactivated fetal bovine serum (FBS) (Gibco). L3055 cells were maintained in similar medium, but containing 10% v/v serum supreme FBS (Amersham International, Amersham, UK). The L3055 subclones transfected with bcl-2 and bcl-x L have been described in detail in our previous studies. [15] [16] [17] Primary BL mononuclear cell preparations from diagnostic peripheral blood and bone marrow samples were provided by the Immunodiagnostic Laboratory with local regional ethical committee (LREC) approval.
Treatments
CA was stored at À201C as a 0.5 M stock in ethanol, and ATRA, MPA and Dex as 1 mM, 5 mM and 10 mM stocks, respectively, in DMSO (all from Sigma, Dorset, UK). All experiments included appropriate carrier controls. 
Assessment of cell proliferation and differentiation
/PI
Àve cells are deemed apoptotic. Mitochondrial depolarisation was assessed using the JC-1 cationic dye as described previously. 17 Cells were incubated with 10 mM of JC-1 for 30 min before being visualised on an LSM 510 confocal microscope (Zeiss, Germany). JC-1 exhibits potential-dependent accumulation in mitochondria accompanied by a shift in fluorescence emission from 525 nm (green) to 590 nm (red). Mitochondrial membrane depolarisation is indicated by a decrease in the red/green fluorescence ratio.
Caspase activity was detected as described previously using the CaspaTag Caspace Activity Kit (Intergen, Oxford, UK). 17 Cells cultured under the conditions indicated in the text were harvested into 300 ml of culture medium at a cell density of 10 6 cells/ml, followed by the addition of 10 ml of a 30 Â working solution of FAM-VAD-FMK. Cells were then incubated for 1 h at 371C under 5% CO 2 protecting the tubes from light. At the end of the incubation, they were washed twice in 2 ml of 1 Â washing buffer, followed by addition of 2 ml of PI to distinguish dead cells from live cells, then analysed on an EPICS XL-MCL flow cytometer.
Statistical analysis
Error bars where shown and when quoted in the text are standard errors of the mean. Student's t-tests (intraexperimental variation) and paired t-tests (interexperimental variation) were performed using SigmaPlot 2001. For ease of interpretation, reductions in proliferation in response to treatments are quoted in the text as percentage of control [ 3 H]-Tdr incorporation. However, unless otherwise stated t-tests were performed using actual cpm [ 3 H]-Tdr incorporated to allow for the variation within the control group.
Results
Clofibric acid and medroxyprogesterone acetate, but not all-trans retinoic acid, inhibit the proliferation of BL cell lines ATRA (10-100 nM) failed to inhibit the proliferation of Daudi, Raji or L3055 BL cells (Figure 1a ). Indeed at 72 h, 100 nM ATRA appeared to increase [ 3 H]-Tdr incorporation by L3055 cells, although this did not reach statistical significance. These data are consistent with studies described by others and do not support efforts to use retinoids in the treatment of BL. However, we have shown previously that CA and MPA each enhance the activity of ATRA against AML cells and wished to investigate whether they might also sensitise BL cells to ATRA. We therefore exposed Daudi, Raji and L3055 cells to 10, 50 and 100 nM ATRA alone or in combination with CA (0.5 mM), MPA (5 mM) or both (CA/MPA). Although, no ATRA-dependent decreases in The doses of CA and MPA used in the experiments described above were predetermined in our studies of AML cells. 13, 14 However, to confirm that these doses of CA and MPA were required to induce growth inhibition of BL cells, we exposed L3055 cells to a combined two-fold dilution series of the drugs. However, as shown in Figure 1e , reducing the concentration of either drug resulted in the diminution of the cells response. We therefore proceeded to use the initial drug concentrations in all subsequent experiments.
Clofibric acid and medroxyprogesterone acetate inhibit the in vitro proliferation of primary BL cells
The doses of CA and MPA used in our studies are commensurate with those used clinically in the treatment of hyperlipidaemia and breast cancer, respectively. 19, 20 Both drugs are well tolerated at these doses and are associated with minimal toxicities. Consequently, these agents could be considered as possible adjuvants to currently used BL therapies. It was therefore important to ascertain whether the potent action of CA/MPA against BL cell lines was mirrored by similar activities against primary BL cells. 3 H]-Tdr incorporation by all BL cell lines, the response of the primary samples was more variable with only one sample showing a significant reduction (4278.8%; P ¼ 0.0046). The other samples produced increased counts with respect to controls of 115 and 190%, the latter of which was significant (P ¼ 0.011). In contrast, MPA was consistently antiproliferative against primary BL cells, reducing DNA synthesis in all three samples to 1371.4-2576.9% of controls (P ¼ 0.0012-0.00022). Thus, MPA alone was more potent against the primary samples than against the cell lines and more potent than CA alone. However, despite the proproliferative action of CA against two of the primary BLsamples, the combination of CA and MPA remained more antiproliferative than MPA alone. This was most striking in the case of the sample that showed a 190% increase in proliferative response to CA alone (see above). In this sample, MPA alone reduced [ 3 H]-Tdr incorporation to 2576.9% of Fibrates Figure 1f also shows data from primary BL cell cultures treated with 10 nM dexamethasone (Dex). Dex induces apoptosis of malignant B cells and is frequently used in the treatment of highgrade non-Hodgkin lymphomas particularly when CNS involvement is identified or suspected. [21] [22] [23] As expected, Dex was a powerful inducer of apoptosis in two of the patient samples reducing [ 3 H]-Tdr incorporation to 2.570.9 and 6.770.3 of parallel controls (P ¼ 0.00015 and 0.00016). However, as in the case for both CA and MPA, the antiproliferative actions of Dex alone did not reach significance in the case of meaned data across all three samples (Figure 1f ). This was because of the relative insensitivity of the third sample (P ¼ 0.08). Thus, among the primary samples tested, the combination of CA and MPA was more consistent and statistically more significant than Dex alone. In addition, it is also important to note that there was no correlation between Dex sensitivity of primary BL cells and their sensitivity to either CA or MPA.
Clofibric acid and medroxyprogesterone inhibit [ 3 H]-Tdr incorporation by the induction of apoptosis
The above data demonstrated that the actions of CA/MPA against BL cell lines extend to primary BL cells and taken together the data support the consideration that the combination of CA and MPA may have potential benefit in the treatment of BL. To better understand the action of these drugs against BL cells, we focused our remaining studies upon a more detailed analysis in the well-characterised L3055 cell line. Consistent with the [ 3 H]-Tdr incorporation data, we readily observed mitotic figures on 24 h cytocentrifuge preparations of both control and CA/MPA-treated cells (not shown). However, apoptotic figures were more readily detected in the 24 h treated cultures than controls. Furthermore, 72 h treated cultures contained fewer viable cells than parallel controls and fewer cells than that used to set the cultures at t 0 . These observations indicated that the diminished [ 3 H]-Tdr incorporation in response to CA/MPA treatment was mediated by apoptosis rather than mere growth arrest.
To further investigate the apoptotic potential of CA/MPA in BL cells, we performed FACS analyses of caspase activation using FAM-VAD-FMK that irreversibly binds active caspases and also determined rates of necrosis and apoptosis in CA/MPA-treated cultures using dual labelling with Syto-16 and propidium iodide (PI). As in our previous study, activated caspases were already detectable in approximately B25% of control L3055 cells corresponding to the spontaneous/ background apoptosis that occurs in BL cells both in vivo and in vitro. However, after 48 h exposure to CA/MPA, the proportion of cells expressing activated caspases had risen to B65% (Figure 2a, b) .
Although CA has been used successfully in the treatment of human disease it has, as of late, been succeeded by the alternative fibrate drug bezafibrate (Bez) and therefore in some countries CA is no longer available for clinical use. Importantly however, as shown in Figure 2a and 18 Use of this assay confirmed that both CA/MPA and Bez/ MPA equally induced significant apoptosis of L3055 cells (Figure 2c, d) Àve /PI Àve apoptotic cell gate. Apoptosis induced by CA/MPA or Bez/MPA was also associated with mitochondrial membrane depolarisation as determined by using the fluorescent probe JC-1. Both treatments resulted in a loss of the red signal associated with aggregated JC-1 (that also shows as yellow when colocalized with JC-1 monomers) and a shift towards more disseminated green staining indicative of JC-1 monomers (Figure 2e ).
Overexpression of bcl-2 and bcl-x L protect against the antiproliferative effects of CA/MPA
We further investigated the antiproliferative actions of CA/MPA and Bez/MPA using L3055 cells stably transfected to express the antiapoptotic survival genes bcl-2 and bcl-x L . As shown in Figure 3 studies of [ 3 H]-Tdr incorporation demonstrated that control vector-transfected L3055 cells had responses similar to CA and MPA, either alone or in combination, as the parental nontransfected cells (see Figure 1b) . In contrast, both CA and MPA were significantly less potent against bcl-2 or bcl-x L transfectants. Protection against CA/MPA was most apparent at 72 h, when [ 3 H]-Tdr incorporation by vector control cells was reduced to 15.976.9 (P ¼ 0.014) of untreated controls compared to 61.1729% (P ¼ 0.069) and 66.6717% (P ¼ 0.80) in bcl-2 and bcl-x L overexpressing cells, respectively.
As shown in Figure 4 , the protection against the antiproliferative actions of CA/MPA by bcl-2 transgene expression was associated with the abrogation of both basal and drug-induced caspase activation, induction of apoptosis and mitochondrial depolarisation. Whereas 2572.9% of untreated control cells expressed activated caspases as measured by FAM-VAD-FMK staining (see Figure 2 ) only 4.371.1% of bcl-2 over expressing cells were positively stained (P ¼ 0.001). Similarly, 1672.7% of untreated control cells were Àve /PI Àve (see Figure 2 ) compared to only 4.371.1% of bcl-2 transfectants (P ¼ 0.007). As shown in Figure 3 , these differences in basal apoptotic rates between vector control L3055 cells and those overexpressing bcl-2 were also reflected in the greater rate of basal [ whereas in control cells, CA/MPA and Bez/MPA increased caspase activation to 6579.9 and 60711%, respectively, and apoptosis to 5677.6 and 4775.5%, respectively. In bcl-2 overexpressing cells, these characteristics remained in the range of 4.3-5.3% (P ¼ 0.001-0.003). In addition whereas mitochondrial depolarisation was readily detectable in either CA/MPA-or Bez/MPA-treated control cells this did not occur in bcl-2 transfectants. Fibrates and MPA and apoptosis in Burkitt's lymphoma S L Fenton et al
Discussion
A striking feature of BL is rapid cell proliferation and consequent fast tumour growth. However, BLs are tumours of the germinal centre (GC) B cells. 24 At the peak of their expansion during an immune reaction, nonmalignant GC B cells have doubling times of 6-7 h indicating that the proliferation of BL cells per se is not abnormal. [25] [26] [27] However, in an immune response, the proliferative burst of GC cells is followed by apoptosis or differentiation to either long-lived memory B cells or antibody-secreting plasma cells. 28 While in situ apoptosis is a feature of BL, it is likely that an imbalance between proliferation and programmed death with inability to undergo differentiation renders the cells malignant. Thus, treatments that target the apoptosis and/or differentiation of BL cells may be of benefit. The studies we have described here show that MPA, CA and Bez induce apoptosis in BL cells. In the case of the primary BL samples studied, the overall efficacy of CA/MPA was similar to that of 10 nM Dex. Importantly, CA/MPA was observed to kill cells efficiently from a patient whose lymphoma cells were refractory to Dex alone in vitro.
The known biological activities of CA and Bez are mediated via the activation of PPARa 29, 30 and this is the mechanism whereby these drugs affect the differentiation and apoptosis of myeloid cells reported by ourselves and other investigators. 13, 31 B cells have been shown to express PPARa 32 and we identified PPARa expression in L3055 cells using RT-PCR (data not shown). Thus, in the light of the near identical response to CA and Bez, it seems most likely that their actions against BL cells are also mediated via PPARa.
We have shown that MPA promotes ATRA-and D 3 -induced myeloid differentiation by inhibition of the constitutive PGD 2 -11-ketoreductase activity of aldo-ketoreductase AKR1C3 14 . This enzyme activity diverts PGD 2 [34] [35] [36] [37] we had expected that inhibition of AKR1C3 activity would also be the mechanism by which MPA induces apoptosis in BL cells. Western blotting using a broad specificity anti-AKR antibody that reacts with AKR1C3 identified an appropriately sized protein expressed in L3055, but we could not detect AKR1C3-like activity using 3a-androstanediol as substrate. Furthermore, we did not observe the PPARg selective antagonist GW 9662 to inhibit the antiproliferative effects of MPA against L3055 cells (data not shown). Therefore, it appears that MPA promotes BL-cell apoptosis independent of PPARg.
Although a synthetic progesterone derivative, MPA also binds glucocorticoid receptors (GRs). [38] [39] [40] We have demonstrated antiproliferative actions of MPA against both primary BL cells and cell lines, but, in contrast to Dex, did not detect significant caspase activation by L3055 cells after 24-48 h treatments with MPA alone. Furthermore, the antiproliferative effect of MPA alone was not as great as that of Dex alone against primary BL cells. Glucocorticoids (GC), including Dex, are able to both transactivate and transrepress gene expression. In a study using normal human lymphocytes, it has been demonstrated that MPA recapitulates the transrepressive activity of GCs, but not the transactivative capacity. Genes repressed by MPA in normal lymphocytes included interleukin 6 (IL-6) and IL-1. 41 The production of IL-6 acts as a proproliferative autocrine signal for in vitro EBV-transformed B cells, although whether this mechanism extends to primary BL cells remains controversial. [41] [42] [43] [44] There is unconvincing evidence that IL-6 serves to support the survival of childhood BL, but there are a growing number of reports that indicate that this mechanism is a key feature of AIDS-related BL and other HIV-associated lymphoproliferative diseases. 42, 43, 45 In contrast, IL-1b is expressed by both EBV-transformed lymphoblastoid cell lines and BL cells and was shown to be upregulated by several EBV latent proteins. 46 Although not generally regarded as a survival signal, an independent study also showed that intracellular IL-1b protects against Fas-mediated apoptosis via competition for binding to ICE (IL-1-converting enzyme). 47 In contrast to MPA, both CA and Bez elevated caspase activation when used alone; thus, it appears that either MPA acts to enhance PPARa-dependent apoptosis or generates a suboptimal apoptotic signal that synergises with that delivered by fibrate drugs. It is therefore, of interest to note that MPA has been found to increase the release of 5-hydroxytryptamine from cells, which was recently shown by us to promote apoptosis of BL cells. 17 Thus, it remains possible that MPA promotes BL cell apoptosis through the intersection of multiple mechanisms.
In summary, our data indicate that combined fibrate/MPA may provide a novel and powerful adjunct to current cytotoxic/ glucocorticoid therapy for BL. The low associated side effects of these drugs combined with the ease of their administration and low costs relative to conventional chemotherapy make fibrates/ MPA treatment a particularly attractive option in endemic BL. In addition, fibrates/MPA treatment may reduce the severity of cytotoxic therapies required to induce remission from BL, a goal that is of particular value in the treatment of patients with BL in association with HIV. Fibrates and MPA and apoptosis in Burkitt's lymphoma S L Fenton et al
